Clinical Study
Cryotherapy for Primary Treatment of Prostate Cancer: Intermediate Term Results of a Prospective Study from a Single Institution
Table 2
Characteristics and Risk stratification.
| | Tumor characteristics |
| | Ng/mL PSA | Median 8.25 (1,818–56,171) | Mean 10.517 95% CI (9,013–12,021) | | Prostate volume (cc) at diagnosis | Median 33 (range 11–91) | Mean 37.13 95% CI (34,13–40,13) | | Gleason | | | | 5 () | 1 (0.9%) | | | 6 () | 54 (50%) | | | 7 () | 19 (17.6%) | | | 7 () | 18 (16.7%) | | | 8 () | 14 (13%) | | | 9 () | 2 (1.9%) | | Stage (adapted according to
TNM 2009 classification) | | | | cT1c | 57 (52.8%) | | | cT2a | 20 (18.5%) | | | cT2b | 16 (14.8%) | | | cT2c | 13 (12%) | | | cT3a | 2 (1.9%) | | | Pathological report | | | | Right side | 33 (30.6%) | | | Left side | 31 (28.7%) | | | Bilateral | 44 (40.7%) | | | RISK (according to D’Amico criteria) | | | | Low | 28 (25.9%) | | | Intermediate | 34 (31.5%) | | | High | 46 (42.6) | | | Hormone treatment | 44 (40.7%) | | | Prostate volume at treatment (cc) | Median 31 (range 14–80) | Mean 32,66 95% CI (30.15–35,17) |
|
|
